Deltex Medical Group plcAGM 28 April 2011

Ewan PhillipsEwan Phillips

Introduction

• World leader in ODM• Intervene – fluid during surgery• Monitor – cardiac output in critical care• Simple – to learn, to use & very safe

• Evidence – robust: clinical & economic• Implementation

• Bottom-up – hospital level by procedure• Top-down – system level standard of care

• World leader in ODM• Intervene – fluid during surgery• Monitor – cardiac output in critical care• Simple – to learn, to use & very safe

• Evidence – robust: clinical & economic• Implementation

• Bottom-up – hospital level by procedure• Top-down – system level standard of care

Platform for growth

• Sales growing• Fastest growth in surgery in UK & US

• High margins• 74% overall• >80% in direct markets

• Stable cost base• Cash positive in second half

Financial Highlights - CashFinancial Highlights - Cash

NICE guidance

• Important validation • Positive recommendation for surgery• Reduce post-operative complications• Reduce cost by circa £1,100 per patient

• Major and high risk surgery• Over 800,000 NHS patients a year• “Dominant” technology

• Still need change in practice and NHS cash

UK growth strategy

• £20 billion savings target• Innovative Technologies Adoption Procurement Programme• National Technology Adoption Centre support• Enhanced recovery – national roll-out

• NICE evaluation pathway• Issued 30 March• Product specific

• Extra income for NHS hospitals under CQUIN• Oesophageal Doppler specific• Enhanced recovery

International growth strategyInternational growth strategy

• US Strategy• Demonstration ‘stories’ from existing accounts• Stand-alone improvement & enhanced recovery• Targeting hospital groupings with ‘quality’ agendas• Quality indicator for surgery

• International Strategy• Build on Paris tender in France• Support Spanish projects to conclusions• ‘Exporting’ NICE, NTAC, CQUIN, enhanced recovery

Summary

• ODM solves a major clinical problem• ODM implementable:

• Stand-alone change in practice• Enhanced recovery surgical programmes

• Evidence key to system wide adoption• NICE guidance is important validation• Growth rates encouraging• Potential for considerable acceleration